Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neuraly, Inc.

Latest From Neuraly, Inc.

Bukwang Adds To Stacking Mid-Stage Failures In Parkinson's

Bukwang and subsidiary Contera have become the latest to fail to progress a novel Parkinson's therapy to late-stage trials after a Phase II miss, although several other Korean firms remain in the race for the challenging indication, albeit mainly in Phase I-II.

South Korea Clinical Trials

Can Incretins Treat Parkinson’s Disease?

Only one biopharma group is actively trialing a GLP-1 agonist in the condition. It might not be alone for long.

Clinical Trials Commercial

AbbVie’s Parkinson’s Plans Back In The PINK With Mitokinin Buy

Just over six months after getting a complete response letter for its prodrug carbidopa and levodopa combination product, the US major has acquired Mitokinin and its selective PINK1 activator which could potentially be a disease-modifying treatment for Parkinson’s disease.

M & A Neurology

Path Ahead For Neuraly’s NLY01 Unclear After Phase II Parkinson’s Disappointment

The US firm’s lead program has flunked a mid-stage trial in early Parkinson’s disease and, despite a promising efficacy signal in a younger patient cohort, its future remains uncertain.

Clinical Trials Neurology
See All

Company Information

  • Industry
  • Biotechnology
  • Other Names / Subsidiaries
    • D&D Pharmatech
UsernamePublicRestriction

Register